Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.
RAINBOWFISH: 2-year efficacy and safety data of Evrysdi in infants with presymptomatic SMA

Professor Laurent Servais shares 2-year efficacy and safety outcomes from the RAINBOWFISH study, assessing Evrysdi in infants with presymptomatic SMA.

 

  • Understand the impact of Evrysdi on meeting important developmental milestones
  • Explore outcomes across bulbar function, ventilation support and cognitive development
  • Examine the safety profile of Evrysdi after 2 years of treatment 


Please click on the magnify/search icon to jump to relevant chapters in the video.

Servais L. Presented at World Muscle Society congress. Prague, Czechia. 8–12 October 2024.

Reference

1. Evrysdi (risdiplam) Summary of Product Characteristics.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or +44 (0)1707 367554.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.